The ligand-binding glycan on dystroglycan serves as a critical mediator for cell–ECM interaction and its disruption leads to dystroglycanopathy, a subset of CMDs affecting brain development and skeletal muscles1. The gene discussed is DAG1; the disease is neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan.